|1.||Dorr, Robert T: 15 articles (08/2014 - 01/2002)|
|2.||Landowski, Terry H: 9 articles (08/2014 - 11/2002)|
|3.||Samulitis, Betty K: 7 articles (04/2012 - 01/2006)|
|4.||Hersh, Evan: 4 articles (10/2010 - 11/2006)|
|5.||Dorr, R T: 3 articles (01/2012 - 09/2000)|
|6.||Dorr, Robert: 3 articles (10/2010 - 05/2007)|
|7.||Briehl, Margaret M: 2 articles (08/2014 - 01/2002)|
|8.||Powis, Garth: 2 articles (06/2012 - 03/2012)|
|9.||Remers, William A: 2 articles (04/2012 - 01/2004)|
|10.||Wisner, Lee: 2 articles (04/2012 - 01/2011)|
08/01/2010 - "Combined phase I/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myeloma."
01/01/2006 - "The current studies compared biological indices of cytotoxicity in 7 human multiple myeloma (MM) cell lines to develop a correlative model for imexon sensitivity. "
01/01/2006 - "Correlates of imexon sensitivity in human multiple myeloma cell lines."
11/01/2002 - "Imexon is a new antitumor agent with high activity in multiple myeloma. "
06/01/2001 - "Imexon is a cyanoaziridine derivative that has antitumor activity in multiple myeloma. "
|2.||Acquired Immunodeficiency Syndrome (AIDS)
01/01/1990 - "Antiviral efficacy of Imexon in the Rauscher murine retrovirus AIDS model."
05/01/1992 - "Imexon (4-imino-1, 3-diazabicyclo-(3.1.0)-hexan-2-one) a cyanoaziridine compound was studied in the treatment of the murine retrovirus-induced immunodeficiency disease model of AIDS (LP-BM5, MAIDS). "
01/01/1991 - "Imexon (4-imino-1,4-diazobicyclo-3.1.0-hexan-2-one) was moderately effective in the treatment of a retroviral infection in a genetically defined murine model. "
01/01/1991 - "Effect of imexon treatment on Friend virus complex infection using genetically defined mice as a model for HIV-1 infection."
04/01/2012 - "Preclinical studies evaluated the anti-tumor activity and mechanism of action of AMP423, a naphthyl derivative of 2-cyanoaziridine-1-carboxamide with structural similarity to the pro-oxidant anti-tumor agent imexon. "
11/01/2009 - "Imexon is already in clinical trials in patients with advanced solid tumors. "
05/01/2007 - "This study evaluated the cytotoxic effects of imexon (NSC-714597) in tumor cells when combined with a broad panel of chemotherapeutic drugs. "
05/01/2007 - "The purpose of this trial was to define the maximum-tolerated dose (MTD), toxicities, pharmacokinetics, and pharmacodynamics of imexon in patients with advanced cancers. "
11/01/2006 - "Imexon, a novel pro-oxidant, thiol-binding agent, is currently in phase I/II clinical trials in patients with advanced solid tumors. "
|5.||Pancreatic Neoplasms (Pancreatic Cancer)
01/01/2011 - "Imexon is a pro-oxidant small molecule which produced a high response rate in combination with GEM in a phase I trial in pancreatic cancer. "
03/01/2012 - "Imexon induces an oxidative endoplasmic reticulum stress response in pancreatic cancer cells."
01/01/2011 - "In three human pancreatic cancer lines, there was additivity for the imexon/GEM combination. "
02/01/2009 - "Inhibition of protein synthesis by imexon reduces HIF-1alpha expression in normoxic and hypoxic pancreatic cancer cells."
01/01/2005 - "Induction of apoptosis and cell cycle arrest by imexon in human pancreatic cancer cell lines."
|1.||Sulfhydryl Compounds (Thiols)
|5.||Glutathione (Reduced Glutathione)
|7.||Caspase 8 (Caspase-8)
|8.||Fibroblast Growth Factor 7
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Combination Drug Therapy (Combination Chemotherapy)
|3.||Drug Therapy (Chemotherapy)